Phase 1 Study of ADI PEG 20 Plus FOLFOX in Subjects With Advanced Gastrointestinal Malignancies

Trial Profile

Phase 1 Study of ADI PEG 20 Plus FOLFOX in Subjects With Advanced Gastrointestinal Malignancies

Recruiting
Phase of Trial: Phase I

Latest Information Update: 21 Sep 2017

At a glance

  • Drugs Pegargiminase (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
  • Indications Gastrointestinal cancer; Liver cancer
  • Focus Adverse reactions
  • Sponsors Polaris Pharmaceuticals
  • Most Recent Events

    • 18 Sep 2017 Planned End Date changed from 1 Oct 2017 to 1 Oct 2019.
    • 18 Sep 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Aug 2019.
    • 21 Jan 2017 Results (n=17) presented at the 2017 Gastrointestinal Cancers Symposium
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top